A Phase 3 interventional study of Aliskiren and Amlodipine in Hypertension, sponsored by Novartis. Completed at 8 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-03-10.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies testing aliskiren in Hypertension — none open to participants now, none under way, none of them phase 3. aliskiren · Hypertension.
Among the 89 studies testing aliskiren in Hypertension, this one is the 29th largest by enrollment, is one of 11 that started in 2006, is one of 38 in phase 3, and was the 31st registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →None of the 89 studies testing aliskiren in Hypertension is open now. The open studies under Hypertension, anywhere →
aliskiren: first FDA approval 2007 (TEKTURNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 39 · Phase 4 34
First in 2001; this study’s year is marked. 11 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 556 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 253 across the 89 interventional studies. Of the 79 that completed or were terminated, 36 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 89 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
228 studies in Hypertension by Novartis: 5 open now, 6 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 228 studies in Hypertension by Novartis, this one is the 72nd largest by enrollment of the 223 interventional ones that give a count, is one of 32 that started in 2006, is one of 108 in phase 3, and was the 99th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 89 studies testing aliskiren in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 228 in Hypertension:
This tab as a report to print or save as PDF → With an account.
To assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg / amlodipine 10 mg in patients with essential hypertension (Mean Sitting Diastolic Blood Pressure [msDBP] ≥ 90 mmHg and \< 110 mmHg).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Drug: Aliskiren · Drug: Amlodipine
Drug: Aliskiren · Drug: Amlodipine · Drug: Hydrochlorothiazide
All patients received aliskiren 150 mg for the first two weeks; dose was then force-titrated to aliskiren 300 mg for 52 weeks duration
All patients received amlodipine 5 mg for the first two weeks; dose was then force-titrated to amlodipine 10 mg for 52 weeks duration
Optional addition of Hydrochlorothiazide (HCTZ)of 12.5 mg with increase to 25 mg was allowed for patients not adequately controlled.
Overall Percentage of Patients With Adverse Events
Time frame: 52 weeks
Change in Mean Sitting Diastolic Blood Pressure (msDBP)From Baseline to the Indicated Time Points
Time frame: Baseline, Week 2, Week 4, Week 6, Week 10, Week 14, Week 28, Week 41 and Week 54
Percentage of Patients Achieving a Blood Pressure Control Target of <140/90 mmHg
Time frame: Baseline, Week 2, Week 10, Week 28 and Week 54
Percentage of Patients Achieving a Response in Mean Sitting Diastolic Blood Pressure (msDBP)
Time frame: Baseline, Week 2, Week 10, Week 28 and Week 54
| Milestone | Aliskiren/Amlodipine | Aliskiren/Amlodipine/HCTZ |
|---|---|---|
| Started | 470 | 86 |
| Completed | 379 | 73 |
| Not completed | 91 | 13 |
| Withdrew: Adverse event | 60 | 7 |
| Withdrew: Unsatisfactory therapeutic effect | 1 | 2 |
| Withdrew: Condition no longer requires study drug | 2 | 0 |
| Withdrew: Protocol deviation | 8 | 0 |
| Withdrew: Patient withdrew consent | 12 | 1 |
| Withdrew: Lost to follow-up | 6 | 3 |
| Withdrew: Administrative problems | 2 | 0 |
| Percentage of Participants | Aliskiren 150mg/ Amlodipine 5mg Alone | Aliskiren 300mg/ Amlodipine 10mg Alone | Aliskiren 300mg/ Amlodipine 10mg/ HCTZ |
|---|---|---|---|
| Overall Percentage of Patients With Adverse Events | 23.6 | 71.2 | 57.0 |
| mm Hg | Aliskiren/Amlodipine | Aliskiren/Amlodipine/HCTZ |
|---|---|---|
| Week 2 (Visit 5) | -8.7 ± 6.94 | -5.9 ± 6.05 |
| Week 4 (Visit 6) | -14.0 ± 6.88 | -11.9 ± 5.58 |
| Week 6 (Visit 7) | -15.7 ± 6.96 | -11.5 ± 7.36 |
| Week 10 (Visit 8) | -16.3 ± 6.69 | -9.3 ± 7.22 |
| Week 14 (Visit 9) | -17.1 ± 6.84 | -13.1 ± 7.64 |
| Week 28 (Visit 10) | -16.7 ± 7.15 | -14.7 ± 8.22 |
| Week 41 (Visit 11) | -17.0 ± 7.26 | -15.4 ± 6.86 |
| Week 54 (Visit 12) | -16.3 ± 7.13 | -15.3 ± 6.55 |
| Week 54 (Visit 12) (LOCF) | -15.7 ± 7.61 | -14.2 ± 7.90 |
| Percentage of patients | Aliskiren/Amlodipine | Aliskiren/Amlodipine/HCTZ |
|---|---|---|
| Week 2 (Visit 5) | 35.3 ± 88.0 | 8.1 |
| Week 10 (Visit 8) | 88.0 | 16.3 |
| Week 28 (Visit 10) | 88.2 | 56.8 |
| Week 54 (Visit 12) | 82.0 | 62.2 |
| Week 54 (Visit 12) (LOCF) | 77.3 | 58.1 |
| Percentage of patients | Aliskiren/Amlodipine | Aliskiren/Amlodipine/HCTZ |
|---|---|---|
| Week 2 (Visit 5) | 61.2 | 38.4 |
| Week 10 (Visit 8) | 96.8 | 61.6 |
| Week 28 (Visit 10) | 95.9 | 85.2 |
| Week 54 (Visit 12) | 93.2 | 89.2 |
| Week 54 (Visit 12) (LOCF) | 90.6 | 84.9 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aliskiren 150mg/ Amlodipine 5mg Alone | — | 0/556 (0%) | 14/556 (2.5%) |
| Aliskiren 300mg/ Amlodipine 10mg Alone | — | 13/546 (2.4%) | 138/546 (25.3%) |
| Aliskiren 300mg/ Amlodipine 10mg/ HCTZ | — | 2/86 (2.3%) | 21/86 (24.4%) |
| Event | Aliskiren 150mg/ Amlodipine 5mg Alone | Aliskiren 300mg/ Amlodipine 10mg Alone | Aliskiren 300mg/ Amlodipine 10mg/ HCTZ |
|---|---|---|---|
| GangreneInfections and infestations | 0/556 | 0/546 | 1/86 |
| HypotensionVascular disorders | 0/556 | 0/546 | 1/86 |
| Atrial fibrillationCardiac disorders | 0/556 | 1/546 | 0/86 |
| DiarrhoeaGastrointestinal disorders | 0/556 | 1/546 | 0/86 |
| Intestinal ischaemiaGastrointestinal disorders | 0/556 | 1/546 | 0/86 |
| AmoebiasisInfections and infestations | 0/556 | 1/546 | 0/86 |
| GastroenteritisInfections and infestations | 0/556 | 1/546 | 0/86 |
| Post procedural infectionInfections and infestations | 0/556 | 1/546 | 0/86 |
| Respiratory tract infectionInfections and infestations | 0/556 | 1/546 | 0/86 |
| Acetabulum fractureInjury, poisoning and procedural complications | 0/556 | 1/546 | 0/86 |
| Event | Aliskiren 150mg/ Amlodipine 5mg Alone | Aliskiren 300mg/ Amlodipine 10mg Alone | Aliskiren 300mg/ Amlodipine 10mg/ HCTZ |
|---|---|---|---|
| Oedema peripheralGeneral disorders | 8/556 | 108/546 | 12/86 |
| Upper respiratory tract infectionInfections and infestations | 5/556 | 32/546 | 5/86 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/556 | 5/546 | 5/86 |
| Age Continuous(years) | Aliskiren/Amlodipine | Aliskiren/Amlodipine/HCTZ | Total |
|---|---|---|---|
| Mean | 54.2 ± 11.66 | 55.7 ± 11.33 | 54.4 ± 11.61 |
| Sex: Female, Male(Participants) | Aliskiren/Amlodipine | Aliskiren/Amlodipine/HCTZ | Total |
|---|---|---|---|
| Female | 196 | 30 | 226 |
| Male | 274 | 56 | 330 |
The record gives a start of Nov 2006, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aliskiren · Amlodipine